IngredientsSphaerotrichia is a genus of brown marine macroalgae (seaweed) formally described by the Swedish phycologist Harald Kylin in 1940. According to the World Register of Marine Species (WoRMS), Sphaerotrichia divaricata occupies the following taxonomic position: Kingdom Chromista, Subkingdom Harosa, Infrakingdom Heterokonta, Phylum Ochrophyta, Class Phaeophyceae, Subclass Fucophycidae, Order Ectocarpales, Family Chordariaceae, Genus Sphaerotrichia.
The genus was formally established in its original publication: Kylin, H. (1940). Die Phaeophyceenordnung Chordariales. Acta Universitatis Lundensis 36(9): 1–67. The primary species, Sphaerotrichia divaricata, is the type species (holotype) of the genus. The most recent taxonomic treatment adopted for the genus is: Silberfeld, T., Rousseau, F. & Reviers, B. de (2014). An updated classification of brown algae (Ochrophyta, Phaeophyceae). Cryptogamie Algologie 35(2): 117–156.
The genus Sphaerotrichia currently encompasses two closely related species of primary research interest:
A number of now-unaccepted synonyms have accrued over the taxonomic history of the genus, including: Chordaria divaricata C. Agardh, 1817 (the original basionym); Castagnea divaricata (C. Agardh) J. Agardh, 1882; Nemacystus divaricatus (C. Agardh) Hygen, 1934; Sphaerotrichia japonica Kylin, 1940; Sphaerotrichia chordarioides Yamada, 1944; and Sphaerotrichia divaricata f. typica Inagaki, 1954.
Common vernacular names documented across languages include: "Slippery Tangle Weed" in English; Blød vinkeltang in Danish; gaffelgrenad slemtång and gaffelgrenig slemtråd in Swedish; gaffelslemming in Swedish/Norwegian; and gaffeltrevl in Norwegian Bokmål and Nynorsk. In Japan, the organism is most widely known under its traditional name Ishimozuku (石もずく), literally "stone mozuku." Sphaerotrichia divaricata is an edible brown alga harvested from Hokkaido to Kyushu of Japan. Its morphology resembles that of Okinawa-mozuku (Cladosiphon okamuranus), but they are different species.
Plants are epilithic or epiphytic, attached by a small disc, solitary or caespitose, terete, solid and later becoming hollow, slightly gelatinous, irregularly dichotomously or alternately branched several times, gradually attenuated towards the apex, yellowish to dark brown in color, haplostichous, composed of several layers of colorless, large, elongated medullary filaments, pigmented roundish cortical cells, and 3–5-celled assimilatory filaments. Each cell contains several chloroplasts with pyrenoids. Rhizoidal filaments are often present in the central hollow area. Terminal cells of assimilatory filaments are obviously swollen and larger than the cells below them.
The characteristic brown coloration of Sphaerotrichia results from the dominance of the xanthophyll fucoxanthin, which masks the other pigments — Chlorophyll a and c (but no Chlorophyll b), beta-carotene, and other xanthophylls.
Culture studies by Ajisaka and Umezaki (1978) on Japanese S. divaricata reported a typical heteromorphic life history with sexual reproduction. Unispores developed into bushy filamentous gametophytes forming uniseriate plurilocular sporangia. Those plurispores copulated and the zygote developed into erect thalli forming unilocular sporangia. Unfused gametes reproduced gametophytes. Chromosome counts in the diploid sporophyte were 2n = 18–24. Peters and others (1987) cultured several strains of S. divaricata from the North Pacific and North Atlantic and showed a sexual heteromorphic life history between dioecious filamentous gametophytes and erect thalli; they reported the chromosome number of S. divaricata as n = 14–18.
Sphaerotrichia is mainly distributed in temperate areas of the Pacific and Atlantic Oceans and has been recently introduced to the Mediterranean coast. S. divaricata is harvested from Hokkaido to Kyushu of Japan. Ribera et al. (1992) reported S. divaricata from Turkey and the Thau Lagoon in France. Its range extends into the North Atlantic, including the waters around northern Europe.
In Japan, both Okinawa-mozuku and Ishimozuku are consumed as edible algae. Most Okinawa-mozuku is farm-raised in Okinawa Prefecture, and it is used in diverse applications as a food material or functional food ingredient because of its strong stickiness. However, Ishimozuku is less popular in markets, probably because the toughness or texture of its algal body is somewhat harder compared to Okinawa-mozuku. Ishimozuku is a specialty product of Aomori, at the far northern end of Japan's main island.
In terms of preparations used in research and as dietary supplements, Sphaerotrichia has been studied in the following forms:
Various types of algae have been included in the traditional diets of residents of the Far East and Hawaiian Islands, including Japan, Korea, and China. Within this broader cultural tradition, Ishimozuku (Sphaerotrichia divaricata) has had a specific and geographically circumscribed culinary history in northern Japan.
S. divaricata is an edible brown alga harvested from Hokkaido to Kyushu of Japan, morphologically resembling but taxonomically distinct from Cladosiphon okamuranus. In Japan, both Okinawa-mozuku and Ishimozuku are edible algae. Ishimozuku is a special product of Aomori, at the far northern end of Japan's main island. Its use as a food thus represents a long-standing regional culinary tradition in northern Honshu, where local communities have harvested the alga from coastal rocky substrates.
Algae containing specific polysaccharides have been used as polysaccharide thickeners and gelling agents for various industrial applications. Recent reports have described that these components show interesting biological activity; furthermore, water-soluble components have shown immune system modulation and anti-hypertension activity properties. Polysaccharides in the human body may improve the intestinal environment and suppress the absorption of extra lipids and cholesterol in the small intestine. Some of these beneficial components are used today as functional food materials.
No formal ethnopharmacological record has been documented in peer-reviewed literature attributing specific medicinal claims to Sphaerotrichia as distinct from other mozuku-type seaweeds in traditional Japanese medicine. The primary traditional context is dietary rather than medicinal: Ishimozuku was consumed as a regional food source and as part of the broader pattern of seaweed-rich diets common in coastal Japanese communities. However, Ishimozuku is not widely popular in markets, probably because the toughness or texture of its algal body is somewhat harder compared to Okinawa-mozuku. Its lower market penetration relative to Cladosiphon okamuranus means that the historical dietary use, while genuine, has been geographically limited to northern Japan and has not been systematically documented over specific centuries in the scholarly literature retrieved.
As a brown alga of the class Phaeophyceae, Sphaerotrichia contains the full spectrum of bioactive compounds characteristic of this class. The following constituents have been identified or measured in the species or are established components of closely related Chordariaceae algae.
Fucoxanthin is an orange-colored pigment predominantly found in brown algae (Phaeophyceae) and diatoms (Bacillariophyceae). It belongs to the class of xanthophylls and non-provitamin A carotenoids. The compound is chemically designated as 3′-acetoxy-5,6-epoxy-3,5′-dihydroxy-6′,7′-didehydro-5,6,7,8,5′,6′-hexahydro-β,β-carotene-8-one, with a molecular formula of C₄₂H₅₈O₆. Fucoxanthin is present in brown seaweeds belonging, among others, to the genera Dictyota, Ecklonia, Fucus, Hijikia, Laminaria, Petalonia, Sargassum, Scytosiphon, Sphaerotrichia, and Undaria.
Quantitative measurements made directly in S. divaricata have established it as a particularly rich source of fucoxanthin relative to other mozuku seaweeds. Fucoxanthin contents measured by HPLC analysis in Ishimozuku ranged from 105.6 to 1148.5 μg/g dry weight. Total polyphenol contents of Ishimozuku were 0.296–0.958 mg/g dry weight, which were higher than those of Okinawa-mozuku (0.082 ± 0.011 mg/g dry weight). The average fucoxanthin content of Ishimozuku was 557.9 ± 93.8 μg/g dry weight, compared to 153.8 ± 5.80 μg/g dry weight for Okinawa-mozuku. These data indicate that Ishimozuku contains approximately 3.6 times more fucoxanthin on average than the more commercially prevalent Okinawa-mozuku.
Brown seaweed contains a variety of compounds including phlorotannins, fucoxanthin, fucoidan, alginate, and laminarin. Phlorotannins are a unique class of polymers synthesized by brown seaweed (Phaeophyta), exhibiting structural resemblance to tannins found in land plants and characterized by high hydrophilicity and molecular weights ranging from 126 Da to 650 kDa. In S. divaricata, brown algae normally have various polyphenols such as gallic acid, catechin, epicatechin, and phlorotannins. These bitter components function in preventing predation by predatory animals such as sea urchins and shellfish.
Research has increasingly focused on brown algae due to their rich content of bioactive compounds exhibiting antimicrobial, anticancer, antioxidant, anti-inflammatory, antidiabetic, and antiparasitic properties. Key constituents including phlorotannins, fucoxanthin, alginic acid, fucoidan, and laminarin have been widely studied for their chemical composition and functional bioactivities. Fucoidan is a long-chain, sulfated, fucose-rich polysaccharide found in the cell walls of Phaeophyceae (brown algae) reported with several bioactive properties, including anticancer, antiviral, anti-inflammatory, immunomodulatory, prebiotic, wound healing, and anti-ulcer activities. While fucoidan has not been isolated and quantified from Sphaerotrichia specifically in the recovered literature, its presence is consistent with class-level biochemistry of Phaeophyceae.
Ishimozuku (Sphaerotrichia firma) is one species of edible brown algae in Japan, and its lipids are rich in fucoxanthin and n-3 unsaturated fatty acids. Brown algae, including wakame, contain fucoxanthin as well as n-3 polyunsaturated fatty acids found in marine products such as eicosapentaenoic acid (EPA) and stearidonic acid. These fatty acids reportedly improve arteriosclerosis and non-alcoholic steatohepatitis (NASH).
Antioxidant action: Fucoxanthin has no provitamin A activity, but shows strong antioxidant properties, as do other carotenoids. In S. divaricata extracts specifically, the anti-oxidation effects of Ishimozuku accompanied its polyphenol content, and results suggest that Ishimozuku contains various anti-oxidant components with high potential to promote human health.
Anti-obesity via UCP1 induction: Dietary fucoxanthin induces expression of uncoupling protein 1 (UCP1) and plays an important role in energy expenditure in white adipose tissue; because of this unique mechanism, it has attracted much attention in the food industry and nutrition studies.
Anti-cancer and pro-apoptotic mechanisms: Fucoxanthin was found to be the strongest inducer of apoptosis and anti-proliferation in human cancer cells among 15 investigated dietary carotenoids. It reportedly has anti-tumor properties and prevents carcinogenesis in mice. More specifically, fucoxanthin induces cell growth arrest, apoptosis, and/or autophagy in several cancer cell lines as well as in animal models of cancer; fucoxanthin treatment leads to the inhibition of metastasis-related migration, invasion, epithelial–mesenchymal transition, and angiogenesis; and fucoxanthin also affects DNA repair pathways, which could be involved in the resistance phenotype of tumor cells.
Metabolic conversion: In vivo, the bioactive forms of fucoxanthin are fucoxanthinol and/or amarouciaxanthin. When ingested, fucoxanthin is mainly metabolized to fucoxanthinol in the gastrointestinal tract by digestive enzymes such as lipase and cholesterol esterase by hydrolysis.
Hepatic lipogenesis suppression (Sphaerotrichia-specific animal data): In a study using KK-Aʸ mice fed Sphaerotrichia firma lipids, liver triglyceride contents and serum triglyceride concentrations were significantly lower in the Ishimozuku group than in the control group. Results showed that acetyl-CoA carboxylase (ACC) and stearoyl-CoA desaturase (SCD-1) mRNA expression were suppressed in the livers of Ishimozuku group mice. These findings indicate that the lipid-lowering effect operates at least partly via transcriptional suppression of key lipogenic enzymes.
Phlorotannins have a wide range of therapeutic biological actions, including antimicrobial, antidiabetic, antioxidant, anticancer, anti-inflammatory, and anti-adipogenesis activities. Their antioxidant action is mediated through free-radical scavenging, metal ion chelation, and modulation of oxidative stress response pathways.
Although some studies have shown the bioavailability of fucoxanthin in brown seaweeds to be low in humans, many studies have suggested that a dietary combination of fucoxanthin and edible oil or lipid could increase the absorption rate of fucoxanthin, and thus it might be a promising marine drug. This is mechanistically relevant to Ishimozuku preparations, given that the alga's lipid fraction itself contains n-3 fatty acids that could facilitate fucoxanthin solubilization and micellarization in the gastrointestinal tract.
It is important to note at the outset that no human clinical trials have been conducted specifically on Sphaerotrichia as a defined intervention. The scientific evidence is derived from: (a) analytical/compositional studies of Sphaerotrichia itself; (b) animal studies using Sphaerotrichia material; and (c) broader human and clinical evidence pertaining to fucoxanthin — Sphaerotrichia's predominant bioactive — derived from other brown algae. Evidence strengths are clearly designated for each category.
Study type and species: In vitro analytical study on S. divaricata samples (Maeda et al., 2018, Marine Drugs).
The study analyzed fucoxanthin and antioxidant compound contents of Ishimozuku harvested off the northern coast of Japan from 2014 to 2016. Ethanol extract solutions (80%) were prepared from several west coast areas of Aomori, Japan. Polyphenol content was analyzed using the Folin–Ciocalteu method. Anti-oxidative effects were analyzed by DPPH radical scavenging activity and hydrogen peroxide scavenging activity.
Results: Samples d, e, and j showed high anti-oxidative activity in the Ishimozuku samples. Compared to the Ishimozuku extract, the Okinawa-mozuku extract showed low anti-oxidative activity in both experiments. The highest DPPH activity was estimated equal to a pyrogallol solution of 10.3 ± 0.03 mg/L; the average DPPH radical scavenging activity of Ishimozuku was 3.32 ± 0.61 mg/L.
Evidence strength: Preliminary; in vitro only. No human data exist for this species specifically. The results establish compositional superiority of S. divaricata over C. okamuranus in terms of polyphenol content and free-radical scavenging capacity in laboratory assays, but do not permit clinical extrapolation.
Study type and species: Animal (murine) dietary intervention study using S. firma (Ishimozuku) lipid extract (Shibata, Fukuda, Terasaki & Maeda, 2024, Frontiers in Sustainable Food Systems).
Ishimozuku lipids contained fucoxanthin at approximately 44.71 ± 0.02 mg/g. KK-Aʸ mice were fed with either a high-fat diet (control) or a high-fat diet supplemented with 0.5% Ishimozuku lipids for 4 weeks. Liver triglyceride contents and serum triglyceride concentrations were significantly lower in the Ishimozuku group than in the control group. Acetyl-CoA carboxylase (ACC) and stearoyl-CoA desaturase (SCD-1) mRNA expression were suppressed in the livers of Ishimozuku group mice.
Evidence strength: Preliminary; preclinical animal data only. No human clinical trials exist for any Sphaerotrichia species. The results are consistent with the known mechanism of fucoxanthin-induced suppression of lipogenic gene expression but cannot be extrapolated to humans without further study.
More recently, fucoxanthin — Sphaerotrichia's principal bioactive carotenoid — has been reported to have anti-obesity, anti-diabetic, and anti-cancer effects. The human clinical evidence for these effects, however, is extremely limited across all fucoxanthin sources.
Fucoxanthin has remained the most popular option for anti-cancer and anti-tumor activity research, followed by protection against inflammatory, oxidative stress-related, nervous system, obesity, hepatic, diabetic, kidney, cardiac, skin, respiratory, and microbial diseases in a variety of model systems. Despite much pharmacological evidence from in vitro and in vivo findings, fucoxanthin in clinical research is still not satisfactory, because only one clinical study on obesity management was reported in the last five years (up to 2022).
Evidence strength: For fucoxanthin generically — largely preclinical; for Sphaerotrichia specifically — no human data.
Fucoxanthin has antioxidant and anti-inflammatory properties, as well as several anticancer effects. It induces cell growth arrest, apoptosis, and/or autophagy in several cancer cell lines and in animal models of cancer. Fucoxanthin treatment leads to the inhibition of metastasis-related migration, invasion, epithelial–mesenchymal transition, and angiogenesis.
Evidence strength: In vitro and animal data only for all sources including Sphaerotrichia. No human clinical oncology trials have been conducted using Sphaerotrichia-derived material.
One human study examined antithrombotic effects of fucoxanthin and fucoidan derived from Laminaria japonica: Ren et al. (2013) investigated whether fucoxanthin or fucoidan exhibited anti-thrombotic effects; they prepared three types of capsules from Laminaria japonica containing 1 mg fucoxanthin, 400 mg fucoidan, and both, and administered them to 24 volunteers for 5 weeks. The dose of fucoidan or fucoidan + fucoxanthin significantly shortened the lysis time of the thrombus measured by a global thrombosis test in the blood, but fucoxanthin alone did not. Dietary fucoidan increased production of H₂O₂ and the secretion of prostacyclin (PGI2), a potent inhibitor of platelet aggregation. This study was not conducted with Sphaerotrichia material and its findings regarding fucoxanthin alone were negative.
Evidence strength: There is no cardiovascular clinical evidence specific to Sphaerotrichia. The single human study cited above used different algal material and found no independent effect of fucoxanthin on thrombosis endpoints.
The 2024 Sphaerotrichia firma mouse study also analyzed the effects of dietary Ishimozuku lipids on intestinal metabolite component production in obese model mice. Improvements in short-chain fatty acid production were observed, consistent with beneficial shifts in gut fermentation substrates, though precise mechanistic details in Sphaerotrichia-specific publications were not fully elaborated in the retrieved data. More broadly, water-soluble polysaccharide components from seaweeds have demonstrated immune system modulation and anti-hypertension activities; polysaccharides in the human body may improve the intestinal environment; and polysaccharides may additionally suppress the absorption of extra lipids and cholesterol in the small intestine.
Evidence strength: Preclinical animal data only for Sphaerotrichia; broader class-level evidence for seaweed polysaccharides in intestinal health is mechanistically supportive but not human-validated for this genus.
Based on its documented constituent profile and the available research, Sphaerotrichia is associated with the following physiological systems and areas of investigation:
No established clinical dosage regimens exist for Sphaerotrichia as a dietary supplement or medicine. The following dosages are those reported in research studies only:
No pharmacopoeial monograph exists for Sphaerotrichia, and no dose has been established by regulatory bodies such as the NIH Office of Dietary Supplements, EFSA, EMA, or WHO. No safe upper limit has been defined for Sphaerotrichia as a species-specific supplement.
Despite extensive pharmacological evidence from in vitro and in vivo findings, fucoxanthin in clinical research is still not satisfactory, and only one clinical study on obesity management was reported in the last five years (to 2022). Pharmacokinetics, safety, toxicity, functional stability, and clinical perspective of fucoxanthin are substantially addressed in the literature. Nevertheless, fucoxanthin and its derivatives have been shown to be safe, non-toxic, and readily available upon administration.
Toxicological studies in animals present the safety of fucoxanthin application at doses of 200 mg/kg body weight and higher. More extensive animal experimentation and well-controlled clinical trials are suggested for further studies.
Although some studies have shown the bioavailability of fucoxanthin in brown seaweeds to be low in humans, many studies have suggested that a dietary combination of fucoxanthin and edible oil or lipid could increase the absorption rate of fucoxanthin. This has a practical implication for any Sphaerotrichia-based supplement formulation: preparations that retain or are co-administered with the lipid fraction of the alga may deliver greater bioavailable fucoxanthin than aqueous or dried preparations alone.
As a brown seaweed, Sphaerotrichia is expected to contain iodine, as is common to Phaeophyceae. While the recovered literature does not report specific iodine levels for Sphaerotrichia, high-iodine intake from any brown seaweed is a known consideration in populations consuming large amounts of seaweed, particularly for individuals with thyroid disorders. This is a class-level consideration rather than a Sphaerotrichia-specific documented risk.
Fucoidan — a constituent class found in Phaeophyceae cell walls — has documented bioactive properties including anticoagulant-relevant platelet effects. The documented antithrombotic mechanism in the human study (Ren et al. 2013) involved fucoidan increasing prostacyclin production. Individuals taking anticoagulant or antiplatelet medications should be aware of the theoretical interaction potential if consuming seaweed-derived fucoidan in amounts significantly above typical dietary intake. No drug interaction study has been conducted with Sphaerotrichia-derived material.
Fucoxanthin requires more activity-oriented translational research in humans before it can be used as a multi-target drug. For Sphaerotrichia specifically, the complete absence of human clinical trial data means that efficacy, optimal dosing, contraindications, and drug interactions remain undefined. The safety profile observed for dietary consumption of the whole alga in Japanese food traditions is implicitly favorable — given the long history of ingestion — but has not been formally assessed in controlled studies.
Sphaerotrichia (S. divaricata and S. firma) is a taxonomically well-characterized brown seaweed with a defined compositional profile, most notably an exceptionally high fucoxanthin content relative to other edible mozuku-type algae. Because of Ishimozuku's lower availability compared to Okinawa-mozuku, the contents of its nutrient compounds had until recently remained unclear. The available scientific research consists entirely of:
There are no published human clinical trials using Sphaerotrichia as an intervention. No established dosing guidance, pharmacopoeial monograph, or regulatory opinion has been issued by any major health authority for this genus specifically. Research is needed to characterize fucoidan structure and yield from this species, determine human bioavailability of its fucoxanthin under realistic dietary conditions, and conduct dose-finding and safety studies in human subjects.
Health conditions that Sphaerotrichia may help support.
Body systems that Sphaerotrichia may help support.
Go back